Search results for: 'Preferred Destination for Early Phase Clinical Trials'

As clinical pipelines globally witness a surge in novel complex therapies, the clinical trial industry demands new tools in predictive analytics to improve trial design, planning, and execution. Artificial intelligence is gaining large-scale recognition as support for decentralized trial designs, thus enabling patient-centric clinical trial designs...

The global decentralized clinical trial (DCT) market has been witnessing a continued surge after the COVID-19 pandemic. The accelerated DCT adoption in 2020 was driven by restricted mobility of site investigators, clinical research associates, and patients to participate in trials, which resulted in a significant halt in trial activities worldwide....

17 May 2018  |  North America  |  Market Research

Global Pharma Clinical Trial Patient Recruitment & Monitoring IT Solutions, Forecast to 2020

Wearables and Mobile Technologies Growth Opportunities in Digital Transformation Journey of Clinical Trials

Infographics

×

Key Issues Addressed

Clinical trial sponsors and clinical research organizations (CROs) are facing intense pressure to change the way clinical research is conducted and justify the costs and time involved in the clinical development process. Some of the prevailing challenges in the clinical trial industry include the complexity and cost of conducting clinical trials, t...

Despite the term patient centricity gaining currency in the industry, there is a degree of variability in a companies’ approach and strategic priorities. Frost & Sullivan sees digitization playing a critical role in transforming the clinical trial model from traditional, high-cost, and difficult-to-access centralized settings to more patient-centri...

Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) ma...

The COVID-19 pandemic impact on the biopharmaceutical industry has increased patient-centricity and the adoption of eClinical services digital platforms to manage clinical development programs. Capital investments and co-development recorded an uptick over the last 2 years, focusing on advancing clinical assets and expanding the number of Phase 2 a...

This Frost Radar™ investigates the growth and innovation activity of clinical decision support system (CDSS) providers in their pursuit to help end users take the next best medical care action. A CDSS provides professionals with access to organized clinical knowledge integrated with the patient’s medical profile to improve their health and overall ...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

06 Jul 2021  |  North America  |  Market Research

Global Decentralized Clinical Trial (DCT) Growth Opportunities

Strategic Partnering and M&A Activity in At-home Monitoring Solutions Gain Momentum

Infographics

×

Frost & Sullivan presents post–COVID-19 growth opportunities and strategic imperatives for the global decentralized clinical trials (DCT) market, covering the markets maturity, key participants, adoption drivers and restraints, and recent mergers and acquisitions. The report identifies initiatives by major global contract research organizations (CR...